The global gynecology drugs market reached a value of nearly $38,109.7 million in 2021, having increased at a compound annual growth rate (CAGR) of 3.1% since 2016. The market is expected to grow from $38,109.7 million in 2021 to $49,481.1 million in 2026 at a rate of 5.4%. The market is then expected to grow at a CAGR of 5.6% from 2026 and reach $64,957.5 million in 2031.
Growth in the historic period in the gynecology drugs market resulted from a rise in introduction of drugs with novel mechanisms, a rise in educational tools and awareness on menopause, a rise in long acting reversible contraceptives, a shift in lifestyles, a rise in healthcare awareness and expenditure, government initiatives and an increase in pharmaceutical R&D expenditure. The market was restrained by lack of scientific knowledge on PCOS, safety concerns with hormonal contraceptives and hormonal replacement therapies (HRT), low healthcare access, high costs of drug approval, patent expiration of drugs, pricing pressures from regulators, and regulatory changes.
Going forward, an increase in awareness and use of contraceptives and hormone replacement therapy (HRT), age-related increase in gynecological cancers, a rise in ovarian cancer, prevalence of gynecological diseases, a rise in healthcare expenditure and rising investment to understand the mechanisms of endometriosis and its treatment will drive the market. Factors that could hinder the growth of the market in the future include high costs of drugs.
The gynecology drugs market is segmented by therapeutics into hormonal therapy and non-hormonal therapy. The non-hormonal therapy segment was the largest segment of the gynecology drugs market segmented by therapeutics, accounting for 66.6% of the total in 2021. Going forward, the hormonal therapy segment is expected to be the fastest growing segment in the gynecology drugs market segmented by therapeutics, at a CAGR of 6.0% during 2021-2026.
The gynecology drugs market is also segmented by indication into gynecological cancers, menopausal disorder, polycystic ovary syndrome, contraception, and others indications. The polycystic ovary syndrome segment was the largest segment of the gynecology drugs market segmented by indication, accounting for 26.1% of the total in 2021. Going forward, others indications segment is expected to be the fastest growing segment in the gynecology drugs market segmented by indication, at a CAGR of 5.7% during 2021-2026.
The gynecology drugs market is also segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment was the largest segment of the gynecology drugs market segmented by distribution channel, accounting for 45.3% of the total in 2021. Going forward, online pharmacies segment is expected to be the fastest growing segment in the gynecology drugs market segmented by distribution channel, at a CAGR of 9.6% during 2021-2026.
North America was the largest region in the gynecology drugs market, accounting for 33.3% of the total in 2021. It was followed by the Asia Pacific, Western Europe, and then the other regions. Going forward, the fastest-growing regions in the gynecology drugs market will be Asia Pacific and North America where growth will be at CAGRs of 6.1% and 5.2% respectively during 2021-2026. These will be followed by Western Europe and South America, where the markets are expected to register CAGRs of 5.2% and 5.1% respectively during 2021-2026.
COVID-19 has dramatically affected the care of patients with gynecological cancer. During the peak of the pandemic, treatment of many non-emergency benign gynecological conditions was postponed. A study in the Netherlands reported that cancer diagnoses have decreased dramatically during the pandemic, suggesting that patients cannot reach hospitals and are diagnosed at advanced stages. According to a survey by the Japan Society of Gynecologic Oncology, out of 265 designated training facilities in Japan, a total of 232 facilities responded and reported a decrease in the number of outpatient visits due to reluctance of patients to visit hospitals and the actual number of surgeries also decreased by 3.9% in 2020, compared to 2019. A survey conducted by the charity Cancer Research UK investigating the overall impact of care reported that gynecologic cancers were among the most affected, with 78% patients with gynecologic cancers reporting an impact. The increasing number of COVID-19 infected people had a severe impact on gynecology patient care, especially regarding gynecologic surgeries. According to the COVIDSurg, gynecological cancer study, a global observational cohort study investigating first-line management of women with gynecologic cancer reported that at least 15% of women with gynecologic cancer have suffered disruption to usual first-line surgery.
The global gynecology drugs market is moderately competitive and consists of several major players. The top ten competitors in the market made up to 8.34% of the total market in 2021. Players in the market are implementing various strategies such as launching new products and making acquisitions to consolidate their market positions across the globe. Also, a steep rise in the availability of public fundings for the development of these drugs due to a rise in global burden is also expected to fuel the market. Major players in the market are Merck & Co. Inc., AbbVie, Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., AstraZeneca plc, Amgen Inc., Lupin Pharmaceuticals Inc., TherapeuticsMD Inc., Ferring Holding SA. and others.
The top opportunities in the gynecology drugs market segmented by therapeutics will arise in the non-hormonal therapy segment, which will gain $7,081.8 million of global annual sales by 2026. The top opportunities in the gynecology drugs market segmented by indication will arise in the other indications segment, which will gain $3,075.0 million of global annual sales by 2026. The top opportunities in the gynecology drugs market segmented by distribution channel will arise in the retail pharmacies segment, which will gain $4,345.8 million of global annual sales by 2026. The gynecology drugs market size will gain the most in the USA at $2,908.8 million.
Market-trend-based strategies for the gynecology drugs include companies should consider launching or adopting new treatment developments to treat patients with oncology and endometriosis and give them a longer survival time, focus on development of new menopausal hormone therapy to offer better treatment options, investments in gynecology drugs research that will create new opportunities to create and develop new drugs, increase awareness about benefits of contraceptives and launch new products into the market to fulfill the unmet need from developed and developing countries, develop antibody-drug conjugates (ADCs) targeted therapies to target ovarian cancers, consider entering into strategic collaborations and partnerships to broaden their product portfolios, boost revenues and establish category leadership and focus on combination therapies to overcome drug resistance and reduce morbidity and mortality caused due to traditional cancer treatments.
Player-adopted strategies in the gynecology drugs market includes focus on maximizing consumer attention through strategic collaborations and partnerships and expanding product portfolio by launching new products into the market to meet the demand from people suffering from various gynecology diseases.
To take advantage of the opportunities, the publisher reccomends the gynecology drugs companies to focus on development of new drugs, focus on developing antibody-drug conjugates (ADCs) targeted therapy, expand in emerging markets, scale up through merger and acquisition activity, provide competitively priced offerings, focus on securing long-term supply contracts with healthcare institutions, take initiatives to educate consumers, use big data analytics to improve marketing activities, targeting female population to spread awareness and focus on partnerships with key healthcare providers.
Table of Contents
1. Gynecology Drugs Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction
6.1. Segmentation By Geography
6.2. Segmentation By Therapeutics
6.3. Segmentation By Indication
6.4. Segmentation By Distribution Channel
7. Gynecology Drugs Market Characteristics
7.1. Market Definition
7.2. Market Segmentation By Therapeutics
7.2.1. Hormonal Therapy
7.2.2. Non-Hormonal Therapy
7.3. Market Segmentation By Indication
7.3.1. Gynecology Cancers
7.3.2. Menopausal Disorder
7.3.3. Polycystic Ovary Syndrome
7.3.4. Contraception
7.3.5. Others
7.4. Market Segmentation By Distribution Channel
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Online Pharmacies
8. Gynecology Drugs Market Trends And Strategies
8.1. New Treatment Developments
8.2. Benefits and Treatment Modalities of Menopausal Hormone Therapy
8.3. Increase In Investment In Gynecology Drugs Research
8.4. Societal Change About Contraception In Emerging Markets
8.5. Antibody-Drug Conjugates (ADCs) Targeted Therapy
8.6. Strategic Collaborations And Partnerships
8.7. Combination Therapies
9. Impact Of COVID-19 On The Gynecology Drugs Market
9.1. Impact On Gynecological Patient Care
9.2. Impact On Clinical Trial Management
9.3. Supply Chain Issues
9.4. Future Outlook
10. Global Gynecology Drugs Market Size And Growth
10.1. Market Size
10.2. Historic Market Growth, 2016 - 2021, Value ($ Million)
10.2.1. Drivers Of The Market 2016 - 2021
10.2.2. Restraints On The Market 2016 - 2021
10.3. Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
10.3.1. Drivers Of The Market 2021-2026
10.3.2. Restraints On The Market 2021-2026
11. Global Gynecology Drugs Market Segmentation
11.1. Global Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
11.2. Global Gynecology Drugs Market, Segmentation By Indication, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
11.3. Global Gynecology Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
12. Gynecology Drugs Market, Regional And Country Analysis
12.1. Global Gynecology Drugs Market, By Region, Historic and Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
12.2. Global Gynecology Drugs Market, By Country, Historic and Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13. Asia-Pacific Gynecology Drugs Market
13.1. Asia-Pacific Gynecology Drugs Market Overview
13.1.1. Region Information
13.1.2. Market Information
13.1.3. Background Information
13.1.4. Government Initiatives
13.1.5. Regulations
13.1.6. Regulatory Bodies
13.1.7. Major Associations
13.1.8. Taxes Levied
13.1.9. Corporate Tax Structure
13.1.10. Investments
13.1.11. Major Companies
13.2. Asia-Pacific Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.3. Asia-Pacific Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.4. Asia-Pacific Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.5. Asia-Pacific Gynecology Drugs Market: Country Analysis
13.6. China Gynecology Drugs Market
13.7. China Gynecology Drugs Market Overview
13.7.1. Country Information
13.7.2. Market Information
13.7.3. Background Information
13.7.4. Government Initiatives
13.7.5. Regulations
13.7.6. Regulatory Bodies
13.7.7. Major Associations
13.7.8. Taxes Levied
13.7.9. Corporate Tax Structure
13.7.10. Investments
13.7.11. Major Companies
13.8. China Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.9. China Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.10. China Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.11. India Gynecology Drugs Market
13.12. India Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.13. India Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.14. India Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.15. Japan Gynecology Drugs Market
13.16. Japan Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.17. Japan Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.18. Japan Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.19. Australia Gynecology Drugs Market
13.20. Australia Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.21. Australia Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.22. Australia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.23. Indonesia Gynecology Drugs Market
13.24. Indonesia Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.25. Indonesia Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.26. Indonesia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.27. South Korea Gynecology Drugs Market
13.28. South Korea Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.29. South Korea Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.30. South Korea Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14. Western Europe Gynecology Drugs Market
14.1. Western Europe Gynecology Drugs Market Overview
14.1.1. Region Information
14.1.2. Market Information
14.1.3. Background Information
14.1.4. Government Initiatives
14.1.5. Regulations
14.1.6. Regulatory bodies
14.1.7. Major Associations
14.1.8. Taxes levied
14.1.9. Corporate tax structure
14.1.10. Investments
14.1.11. Major Companies
14.2. Western Europe Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
14.3. Western Europe Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
14.4. Western Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14.5. Western Europe Gynecology Drugs Market: Country Analysis
14.6. UK Gynecology Drugs Market
14.7. UK Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
14.8. UK Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
14.9. UK Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14.10. Germany Gynecology Drugs Market
14.11. Germany Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
14.12. Germany Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
14.13. Germany Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14.14. France Gynecology Drugs Market
14.15. France Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
14.16. France Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
14.17. France Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
15. Eastern Europe Gynecology Drugs Market
15.1. Eastern Europe Gynecology Drugs Overview
15.1.1. Region Information
15.1.2. Market Information
15.1.3. Background Information
15.1.4. Government Initiative
15.1.5. Regulations
15.1.6. Regulatory Bodies
15.1.7. Major Associations
15.1.8. Corporate Tax Structure
15.1.9. Investments
15.1.10. Major Companies
15.2. Eastern Europe Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
15.3. Eastern Europe Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
15.4. Eastern Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
15.5. Eastern Europe Gynecology Drugs Market: Country Analysis
15.6. Russia Gynecology Drugs Market
15.7. Russia Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
15.8. Russia Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
15.9. Russia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
16. North America Gynecology Drugs Market
16.1. North America Gynecology Drugs Overview
16.1.1. Region Information
16.1.2. Market Information
16.1.3. Background information
16.1.4. Government Initiatives
16.1.5. Regulations
16.1.6. Regulatory Bodies
16.1.7. Taxes Levied
16.1.8. Corporate Tax Structure
16.1.9. Investments
16.1.10. Major Companies
16.2. North America Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
16.3. North America Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
16.4. North America Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
16.5. North America Gynecology Drugs Market: Country Analysis
16.6. USA Gynecology Drugs Market
16.7. USA Gynecology Drugs Overview
16.7.1. Country Information
16.7.2. Market Information
16.7.3. Background Information
16.7.4. Government Initiatives
16.7.5. Regulations
16.7.6. Regulatory Bodies
16.7.7. Taxes Levied
16.7.8. Corporate Tax Structure
16.7.9. Investments
16.7.10. Major Companies
16.8. USA Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
16.9. USA Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
16.10. USA Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
17. South America Gynecology Drugs Market
17.1. South America Gynecology Drugs Market Overview
17.1.1. Region Information
17.1.2. Market Information
17.1.3. Background Information
17.1.4. Regulations
17.1.5. Regulatory Bodies
17.1.6. Major Associations
17.1.7. Taxes Levied
17.1.8. Corporate Tax Structure
17.1.9. Major Companies
17.2. South America Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
17.3. South America Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
17.4. South America Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
17.5. South America Gynecology Drugs Market: Country Analysis
17.6. Brazil Gynecology Drugs Market
17.7. Brazil Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
17.8. Brazil Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
17.9. Brazil Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
18. Middle East Gynecology Drugs Market
18.1. Middle East Gynecology Drugs Market Overview
18.1.1. Region Information
18.1.2. Market Information
18.1.3. Background Information
18.1.4. Government Initiatives
18.1.5. Regulations
18.1.6. Regulatory Bodies
18.1.7. Major Associations
18.1.8. Taxes Levied
18.1.9. Corporate Tax Structure
18.1.10. Investments
18.1.11. Major Companies
18.2. Middle East Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
18.3. Middle East Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
18.4. Middle East Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
19. Africa Gynecology Drugs Market
19.1. Africa Gynecology Drugs Market Overview
19.1.1. Region Information
19.1.2. Market Information
19.1.3. Background Information
19.1.4. Government Initiatives
19.1.5. Regulations
19.1.6. Regulatory Bodies
19.1.7. Major Associations
19.1.8. Taxes Levied
19.1.9. Corporate Tax Structure
19.1.10. Investments
19.1.11. Major Companies
19.2. Africa Gynecology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
19.3. Africa Gynecology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
19.4. Africa Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
20. Gynecology Drugs Global Market Competitive Landscape
20.1. Company Profiles
20.2. Merck & Co. Inc.
20.2.1. Company Overview
20.2.2. Products And Services
20.2.3. Business Strategy
20.2.4. Financial Overview
20.3. AbbVie
20.3.1. Company Overview
20.3.2. Products And Services
20.3.3. Business Strategy
20.3.4. Financial Overview
20.4. F. Hoffmann-La Roche Ltd.
20.4.1. Company Overview
20.4.2. Products And Services
20.4.3. Financial Overview
20.5. GlaxoSmithKline Plc
20.5.1. Company Overview
20.5.2. Products And Services
20.5.3. Business Strategy
20.5.4. Financial Overview
20.6. Pfizer Inc.
20.6.1. Company Overview
20.6.2. Products And Services
20.6.3. Business Strategy
20.6.4. Financial Overview
21. Key Mergers And Acquisitions In The Gynecology Drugs Market
21.1. Bharat Serums & Vaccines Acquired Women Health Brand Tidilan
21.2. Carlyle And PAI Partners Agreed To Acquired Theramex
21.3. Organon Acquired Forendo Pharma
21.4. Bayer Acquired KaNDy Therapeutics
21.5. AbbVie Acquired Allergan
21.6. Norgine Acquired Azanta
21.7. True North Acquired Glenmark Pharmaceutical Ltd Gynecology Business
22. Gynecology Drugs Market Opportunities And Strategies
22.1. Global Gynecology Drugs Market In 2026 - Countries Offering Most New Opportunities
22.2. Global Gynecology Drugs Market In 2026 - Segments Offering Most New Opportunities
22.3. Global Gynecology Drugs Market In 2026 - Growth Strategies
22.3.1. Market Trend Based Strategies
22.3.2. Competitor Strategies
23. Gynecology Drugs Market, Conclusions And Recommendations
23.1. Conclusions
23.2. Recommendations
23.2.1. Product
23.2.2. Place
23.2.3. Price
23.2.4. Promotion
23.2.5. People
24. Appendix
24.1. Market Data Sources
24.2. Research Methodology
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher
24.6. Copyright and Disclaimer
Executive Summary
Gynecology Drugs Global Market Opportunities And Strategies To 2031: COVID-19 Impact and Recovery provides the strategists; marketers and senior management with the critical information they need to assess the global gynecology drugs market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
Description:
Where is the largest and fastest growing market for gynecology drugs? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The gynecology drugs market global report answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider gynecology drugs market; and compares it with other markets.
The report covers the following chapters
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report.
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction- The introduction section of the report gives brief introduction about segmentation by geography, segmentation by therapeutics, segmentation by indication and segmentation by distribution channel.
- Market Characteristics - The market characteristics section of the report defines and explains the gynecology drugs market. This section also defines and describes goods and related services covered in the report.
- Trends And Strategies - This section describes the major trends shaping the global gynecology drugs market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Impact of COVID-19 - This section describes the impact of COVID-19 on the gynecology drugs market.
- Global Market Size And Growth - This section contains the global historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2016-2021) and forecast (2021-2026, and 2026-2031) market values and growth and market share comparison by region.
- Segmentation - This section contains the market values (2016-2031) and analysis for different segments.
- Regional Market Size and Growth - This section contains the region’s market size (2021), historic (2016-2021) and forecast (2021-2026, and 2026-2031) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
- Competitive Landscape - This section covers details on the competitive landscape of the global gynecology drugs market, estimated market shares and company profiles for the leading players.
- Key Mergers And Acquisitions - This section gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities And Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions And Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for gynecology drugs providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Scope:
Markets Covered:
- By Therapeutics: Hormonal Therapy; Non-Hormonal Therapy
- By Indication: Gynecological Cancers; Menopausal Disorder; Polycystic Ovary Syndrome; Contraception; Others
- By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned:
Merck & Co. Inc.; AbbVie; Hoffmann-La Roche Ltd.; GlaxoSmithKline Plc; Pfizer Inc.
Countries:
China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
Regions:
Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series:
Five years historic and ten years forecast.
Data:
Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; gynecology drugs indicators comparison.
Data segmentations:
country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing:
Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- Merck & Co. Inc.
- AbbVie
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Pfizer Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 227 |
| Published | July 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 38109.7 Million |
| Forecasted Market Value ( USD | $ 64957.5 Million |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 5 |
